Feng Xu, Ph.D.

Director, Chief Scientific Officer, Co-Founder

Feng Xu has had a good track record of success in drug discovery in the biopharmaceutical industry, spanning a period of over 20 years. Most recently, he was the founder and CEO of Kyphia Pharmaceuticals in China. During his tenure at Kyphia, he oversaw drug discovery efforts in the cancer and pain. The programs were supported by a number of government grants and collaborated with the Founder Group, one of the major companies in IT and healthcare industry in China. Previously, he was associate director of chemistry at Xenoport. During his tenure there of just under 9 years, he oversaw a number of drug discovery programs in the areas of pain and CNS disease. Prior to joining Xenoport in 2001, Dr. Feng Xu began his career in 1997, working in the immune disease and cancer area at Tularik. Over the course of his career, Dr. Feng has been responsible for a number of discovery programs in the pain, inflammation, cancer, antiviral disease areas. Dr. Feng Xu received his Ph.D. in Organic Chemistry from Boston University and completed postdoctoral studies in the laboratories of Professor E. J. Corey (Nobel Laureate) at Harvard University. He is an inventor on over 20 issued patents and 30 publications.